FDA approves Ryoncil (remestemcel-L) for steroid-refractory acute graft versus host disease – Mesoblast Ltd
Mesoblast Limited announced the FDA approved Ryoncil (remestemcel-L) as the first mesenchymal stromal cell (MSC) therapy in the United States. Rynocil is the only MSC therapy approved in… read more.
